Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Plasmodial heme detoxification pathway is essential for malaria parasite survival during its intraerythrocytic stage. As the parasite digests host hemoglobin in its digestive vacuole, it releases large amounts of free heme, which is highly toxic. The parasite detoxifies heme mainly by crystallizing it into inert hemozoin. Key proteins such as Heme Detoxification Protein (HDP) and Histidine-rich protein 2 (HRP2) facilitate this process. Several first-line antimalarial drugs, including chloroquine and artemisinin derivatives, act by inhibiting or interfering with hemozoin formation, causing toxic heme to accumulate and killing the parasite.
Inhibitors bind free heme or interfere with hemozoin crystal formation, preventing neutralization of toxic heme and leading to parasite death. Some drugs (especially chloroquine) bind the heme or its protein scaffold (such as HRP2), disrupt polymerization, and cause toxic heme accumulation. Artemisinin-based drugs alkylate heme and may inhibit heme-homozoin conversion.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodial heme detoxification pathway.